2024
UNDERSTANDING THE IMPORTANCE OF AGE IN SELECTING A TESTING STRATEGY FOR STABLE SYMPTOMATIC PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE: A PRESPECIFIED ANALYSIS FROM THE PRECISE RANDOMIZED TRIAL
Vemmou E, Kelsey M, Vemulapalli S, Mark D, Rogers C, Mullen S, Huey W, Chiswell K, Clare R, Caune A, Yow E, Leipsic J, Byrne R, Ng N, Pier K, Udelson J, Douglas P, Nanna M. UNDERSTANDING THE IMPORTANCE OF AGE IN SELECTING A TESTING STRATEGY FOR STABLE SYMPTOMATIC PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE: A PRESPECIFIED ANALYSIS FROM THE PRECISE RANDOMIZED TRIAL. Journal Of The American College Of Cardiology 2024, 83: 1183. DOI: 10.1016/s0735-1097(24)03173-5.Peer-Reviewed Original Research
2023
Beyond MACE: a multidimensional approach to outcomes in clinical trials for older adults with stable ischemic heart disease
Kalra K, Moumneh M, Nanna M, Damluji A. Beyond MACE: a multidimensional approach to outcomes in clinical trials for older adults with stable ischemic heart disease. Frontiers In Cardiovascular Medicine 2023, 10: 1276370. PMID: 38045910, PMCID: PMC10690830, DOI: 10.3389/fcvm.2023.1276370.Peer-Reviewed Original ResearchStable ischemic heart diseaseIschemic heart diseaseClinical trialsOlder adult populationOlder adultsHeart diseaseHealth outcomesAdult populationMajor adverse cardiovascular outcomesHigh cardiovascular riskAdverse cardiovascular outcomesMultiple chronic diseasesPatient-centered approachCardiovascular clinical trialsPoor health outcomesMore effective careQuality of lifeHolistic health outcomesCardiovascular outcomesCardiovascular riskGeriatric syndromesRandomized trialsPatient populationPatient preferencesChronic diseasesTCT-641 Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials
Sreenivasan J, Reddy R, Jamil Y, Malik A, Chamie D, Howard J, Nanna M, Mintz G, Maehara A, Ali Z, Moses J, Chen S, Chieffo A, Colombo A, Leon M, Lansky A, Ahmad Y. TCT-641 Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2023, 82: b258. DOI: 10.1016/j.jacc.2023.09.652.Peer-Reviewed Original Research
2022
Primary prevention statin therapy in older adults
Nanna M, Abdullah A, Mortensen M, Navar A. Primary prevention statin therapy in older adults. Current Opinion In Cardiology 2022, 38: 11-20. PMID: 36598445, PMCID: PMC9830552, DOI: 10.1097/hco.0000000000001003.Peer-Reviewed Original ResearchConceptsAge 75Older adult populationStatin treatmentRandomized trialsAdult populationPrimary prevention statin therapyOlder adultsAverage lifespan increasesRecent guideline recommendationsACC/AHAOngoing randomized trialsPrevention of morbidityPaucity of evidenceStatin therapyStatin useUSPSTF recommendationsOlder patientsGuideline recommendationsOngoing trialsTreatment recommendationsCardiovascular diseaseTreatment benefitTreatment decisionsGuidelines conflictTrials
2020
In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel.
Nanna MG, Granger CB. In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel. Annals Of Internal Medicine 2020, 173: jc44. PMID: 33075264, DOI: 10.7326/acpj202010200-044.Peer-Reviewed Original Research
2019
A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
Sullivan AE, Nanna MG, Rao SV, Cantrell S, Gibson CM, Verheugt FWA, Peterson ED, Lopes RD, Alexander JH, Granger CB, Yee MK, Kong DF. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization And Cardiovascular Interventions 2019, 96: e102-e109. PMID: 31713326, PMCID: PMC7211549, DOI: 10.1002/ccd.28535.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsAtrial FibrillationCoronary ThrombosisDual Anti-Platelet TherapyFemaleFibrinolytic AgentsHemorrhageHumansMalePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeDouble therapyOral anticoagulationAtrial fibrillationTriple therapyAntithrombotic therapyCoronary syndromeCoronary interventionStent thrombosisMajor adverse cardiovascular eventsTriple antithrombotic therapyAdverse cardiovascular eventsDual antiplatelet therapyOptimal antithrombotic therapyGood safety profileRandom-effects modelIschemic outcomesAntiplatelet therapyCardiovascular eventsP2Y12 inhibitorsMedical managementRandomized trialsIntracranial hemorrhageSafety profile